ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Nome da cripto ABBVON

Classificação No.3262

Capitalização de mercado $0.00

Capitalização de mercado totalmente diluída $0.00

Market share %

Vol. de negociação/Capitalização de mercado (24h) 931,878.60%

Fornecimento circulante 121.31181451

Fornecimento máximo 0

Fornecimento total 121.31181451

Taxa circulante %

Data de emissão --

O preço quando o ativo foi emitido pela primeira vez --

Máximo histórico 237.64005999136555, 2026-03-05

Menor preço 193.3720963640878, 2026-04-29

Blockchain pública ABBVON

Apresentação AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Setor

Midias sociais

• Twitter

• Site oficial
• Explorador de blocos

Análise de entrada de fundos

etfindex:mc_etfindex_source Isenção de responsabilidade: Os dados fornecidos por cmc e não devem ser considerados como conselhos de investimento.